替格瑞洛治疗难治性偏头痛/卵圆孔未闭(TRACTOR):一项开放标签先导研究
这项开放标签先导研究纳入40例有右向左分流且每月偏头痛天数≥6天的患者,给予替格瑞洛治疗28天,17/40(43%)为应答者,应答者继续治疗2个月,偏头痛改善持续。13例(32%)出现药物副作用,无严重不良事件。作者认为替格瑞洛减少偏头痛症状的效果与既往噻吩吡啶类经验相似,但获益似乎较弱且副作用更频繁,使其作为随机试验的选择较差。
要点
- 40例卵圆孔未闭伴右向左分流患者接受替格瑞洛治疗,17/40(43%)每月偏头痛天数减少≥50%。
- 应答者偏头痛改善在3个月治疗期间持续, episodIC与慢性、有或无先兆、不同分流程度间应答率无统计学差异。
- 13例(32%)出现药物副作用,无严重不良事件;作者认为替格瑞洛作为随机试验选择较差。
核心结论
- 替格瑞洛通过P2Y12抑制减少偏头痛症状,效果与作者既往噻吩吡啶类经验相似,但参与者偏头痛获益似乎较弱且副作用更频繁,使其作为随机试验的选择较差。
研究设计与样本
- 开放标签先导研究,纳入40例有右向左分流且每月偏头痛天数≥6天的偏头痛患者,接受替格瑞洛治疗28天,应答者(每月偏头痛天数减少≥50%)继续治疗2个月。
主要发现
- 40例参与者平均年龄36.2岁,平均偏头痛频率17.4天/月,39/40为女性,14/40为发作性偏头痛,26/40为慢性偏头痛,14/40有先兆偏头痛,22/40有中-大右向左分流(Spencer分级≥4)。
- 17/40(43%)为应答者,所有应答者的偏头痛改善持续至3个月治疗期。
- 发作性或慢性偏头痛、有或无先兆、小或较大右向左分流程度的参与者间偏头痛应答率无统计学差异。
- 13例(32%)患者出现药物副作用,无严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: After finding that the thienopyridines clopidogrel and prasugrel reduced migraine headache (MHA) symptoms in some patients with patent foramen ovale (PFO), this small pilot study was undertaken to determine whether ticagrelor, a nonthienopyridine P2Y12 inhibitor, would have similar MHA effects and might be better suited for a future randomized trial. METHODS: MHA patients were screened for PFO. Participants with documented right to left shunt (RLS) and ≥6 monthly MHA days received ticagrelor therapy for 28 days. Those with ≥50% reduction in monthly MHA days were deemed responders and completed 2 additional treatment months. RESULTS: The 40 participants had a mean age of 36.2 years and mean MHA frequency of 17.4 d/mo. A total of 39/40 were female. A total of 14/40 met criteria for episodic MHA, 26/40 for chronic MHA, 14/40 had migraine with aura, and 22/40 had a moderate-large RLS (Spencer grade ≥4). Seventeen of 40 participants (43%) were responders. MHA reduction continued through 3 treatment months in all responders. MHA responder rates were not statistically different in participants with episodic or chronic MHA, with or without aura, or with small/larger RLS shunt magnitude. Thirteen (32%) patients had medication side effects, without serious adverse events. CONCLUSION: P2Y12 inhibition with ticagrelor reduced MHA symptoms similarly to our previous thienopyridine experience, but participants seemed to have a less robust MHA benefit and more frequent side effects than with the thienopyridines, making it an inferior choice for a randomized trial. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ticagrelor reduced MHA symptoms in patients with PFO.
引用
- Reisman AM, Robbins BT, Chou DE, et al. Ticagrelor for Refractory Migraine/Patent Foramen Ovale (TRACTOR): An open-label pilot study. Neurology. 2018. PMID: 30478067. doi:10.1212/WNL.0000000000006573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。